No price history available.
Key financial summary
Financials in GBP| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | £m | 10 | 12 | 17 | 19 | 27 | N/A | N/A | N/A |
| Operating profit | £m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | £m | -5 | -5 | -6 | -3 | 4 | N/A | N/A | N/A |
| EPS reported | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | £m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | £m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | £m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in GBP| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Kromek Group plc, a UK-based entity established in 2013 with headquarters in Sedgefield, specializes in the design, production, and global distribution of advanced radiation detection components and devices. These technologies provide high-resolution data on material composition and structure, serving critical applications across diverse markets such as medical imaging, the civil nuclear sector, CBRNe security, and safety screening. Its reach extends across the United Kingdom, North America, Asia, Europe, Australasia, and Africa. The company's innovative solutions are employed for various purposes, from identifying cancerous tissues and hazardous substances like explosives, to analyzing radioactive materials. Within the civil nuclear industry, Kromek offers sophisticated gamma and neutron detectors, high-specification, high-resolution devices, essential components, and specialized software designed to address complex nuclear detection challenges. These often utilize cadmium zinc telluride (CZT) or scintillator technologies for the detection of gamma rays, x-rays, and neutrons. For medical imaging, their portfolio includes CZT gamma detectors for SPECT, CZT bone mineral densitometry detectors, and cutting-edge photon-counting spectral CT systems. Kromek also provides CBRNE homeland security products and comprehensive solutions for a wide range of clients, including government agencies, border control, airports, seaports, HazMat teams, ambulance crews, police, and armed forces. This offering features specialized gamma spectroscopy software for in-depth sample analysis. Furthermore, the company supports scientific research and development through its CZT imaging development platforms, such as the DMatrix and the EV3500 scalable x-ray CZT linear array, designed for laboratory and research applications. Kromek distributes its products through a combination of distributors, original equipment manufacturers (OEMs), and direct sales channels.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Kromek Group plc, a UK-based entity established in 2013 with headquarters in Sedgefield, specializes in the design, production, and global distribution of advanced radiation detection components and devices. These technologies provide high-resolution data on material composition and structure, serving critical applications across diverse markets such as medical imaging, the civil nuclear sector, CBRNe security, and safety screening. Its reach extends across the United Kingdom, North America, Asia, Europe, Australasia, and Africa. The company's innovative solutions are employed for various purposes, from identifying cancerous tissues and hazardous substances like explosives, to analyzing radioactive materials. Within the civil nuclear industry, Kromek offers sophisticated gamma and neutron detectors, high-specification, high-resolution devices, essential components, and specialized software designed to address complex nuclear detection challenges. These often utilize cadmium zinc telluride (CZT) or scintillator technologies for the detection of gamma rays, x-rays, and neutrons. For medical imaging, their portfolio includes CZT gamma detectors for SPECT, CZT bone mineral densitometry detectors, and cutting-edge photon-counting spectral CT systems. Kromek also provides CBRNE homeland security products and comprehensive solutions for a wide range of clients, including government agencies, border control, airports, seaports, HazMat teams, ambulance crews, police, and armed forces. This offering features specialized gamma spectroscopy software for in-depth sample analysis. Furthermore, the company supports scientific research and development through its CZT imaging development platforms, such as the DMatrix and the EV3500 scalable x-ray CZT linear array, designed for laboratory and research applications. Kromek distributes its products through a combination of distributors, original equipment manufacturers (OEMs), and direct sales channels.